Search

Ancestim

[T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087] … Ancestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes.

RG-7795

Zuclopenthixol

It is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States. … These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.

Protamine sulfate

Despite the relative importance of protamine sulfate's medical indication, the medication can notoriously cause a variety of potentially rare but genuinely severe adverse effects that include systemic … Since it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps

JSM 6427

JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed. It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness ...

Ibalizumab

In October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration.[L43443,L43448] … It has been developed by Taimed biologics and Theratechnologies [L1558, L1554]. This drug was approved in March 2018 for the management of treatment-resistant HIV [L1554].

Haloprogin

The mechanism of action is unknown, but it is thought to be via inhibition of oxygen uptake and disruption of yeast membrane structure and function. … Tinea infections are superficial fungal infections caused by three species of fungi collectively known as dermatophytes (Trichophyton, Microsporum and Epidermophyton).

Tislelizumab

[L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … [A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses.

Atorvastatin

[A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996. … By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease.

Fibrinogen human

It works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting.